AN2 Therapeutics Inc(ANTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.07 | Insider Own | 25.03% | Shs Outstand | 36.3M | Perf Week | 27.61% |
| Market Cap | 0.17B | Forward P/E | - | EPS next Y | 10.61% | Insider Trans | -0.6% | Shs Float | 28.3M | Perf Month | -19.4% |
| Enterprise Value | 0.09B | PEG | - | EPS next Q | -0.2 | Inst Own | 66.36% | Short Float | 10.21% | Perf Quarter | -18.82% |
| Income | -0.04B | P/S | - | EPS this Y | 22.84% | Inst Trans | 5.96% | Short Ratio | 10.85 | Perf Half Y | -3.21% |
| Sales | 0.00B | P/B | 2.17 | EPS next 5Y | 10.92% | ROA | -46.06% | Short Interest | 2.89M | Perf YTD | 297.37% |
| Book/sh | 2.09 | P/C | 2.18 | EPS past 3/5Y | 19.17% -8.39% | ROE | -50.12% | 52W High | -37% ($7.19) | Perf Year | 265.32% |
| Cash/sh | 2.08 | P/FCF | - | Sales past 3/5Y | - | ROIC | -47.78% | 52W Low | 353% ($1.00) | Perf 3Y | -69.1% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 13.97% | Gross Margin | - | Volatility(W/M) | 10.74% 9.1% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.37 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 14.32 | EPS Q/Q | 14.61% | Profit Margin | - | RSI (14) | 54.03 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 14.32 | Sales Q/Q | - | SMA20 | 10.51% ($4.1) | Beta | -0.97 | Target Price | $9 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/11 | SMA50 | -7.48% ($4.9) | Rel Volume | 1.07 | Prev Close | $4.69 |
| Employees | 21 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 25% - | SMA200 | 11.29% ($4.07) | Avg Volume(3M) | 0.27M | Price | $4.53 |
| IPO | 2022/3/25 | Option/Short | Yes/Yes | Trades | 2853 | Volume | 284,726 | Change | -3.41% |
🧬 AN2 Therapeutics (ANTX) is a clinical-stage biotech company that discovers and develops novel small-molecule therapeutics built on its proprietary boron chemistry platform. The company focuses on infectious disease areas with high unmet need, including nontuberculous mycobacterial (NTM) lung disease, and is advancing its pipeline around its lead oral candidate, epetraborole.
Over the past 1 year, roughly in the middle
37% below its 1-year high.
Traded about as much as usual. That is 107% of its average volume.
ANTX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +22.8% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 3 years ago, your return today would be -69.1%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 66.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #316 of 597 in the industry
Based on market cap of $171M.
MDWD#313 MediWound Ltd $172M PER - 
IVVD#314 Invivyd Inc $171M PER - 
ORMP#315 Oramed Pharmaceuticals Inc $171M PER 1.0 ANTX#316 AN2 Therapeutics Inc $171M PER - 
ALXO#317 Alx Oncology Holdings Inc $169M PER - 
FAQ
What kind of company is ANTX?
ANTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ANTX?
The market cap of ANTX is approximately $171M, ranking 4,123 within its sector.
What is the 52-week high and low for ANTX?
ANTX has recorded a 52-week high of $7.19 and a low of $1.00.
